The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Abstract
BACKGROUND: Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery and previous reviews have found them to be effective in reducing blood loss and the need for transfusion. Recently, questions have been raised regarding the comparative performance of the drugs and the safety of the most popular agent, aprotinin. OBJECTIVES: To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE, and the internet. References in identified trials and review articles were checked and trial authors were contacted to identify any additional studies. The searches were last updated in July 2006. SELECTION CRITERIA: Randomised controlled trials (RCTs) of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. Eligible trials compared anti-fibrinolytic drugs with placebo (or no treatment), or with each other. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: This review summarises data from 211 RCTs that recruited 20,781 participants. Data from placebo/inactive controlled trials, and from head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of operative blood loss, but the differences were small. Aprotinin reduced the probability of requiring RBC transfusion by a relative 34% (relative risk [RR] 0.66, 95% confidence interval [CI] 0.61 to 0.71). The RR for RBC transfusion with TXA was 0.61 (95% CI 0.54 to 0.69) and it was 0.75 (95% CI 0.58 to 0.96) with EACA. When the pooled estimates from the head-to-head trials of the two lysine analogues were combined and compared to aprotinin alone, aprotinin appeared superior in reducing the need for RBC transfusion: RR 0.83 (95% CI 0.69 to 0.99). Aprotinin reduced the need for re-operation due to bleeding: RR 0.48 (95% CI 0.35 to 0.68). This translates into an absolute risk reduction of just under 3% and a number needed-to-treat (NNT) of 37 (95% CI 27 to 56). Similar trends were seen with TXA and EACA, but the data were sparse and the differences failed to reach statistical significance. The blood transfusion data were heterogeneous and funnel plots indicate that trials of aprotinin and the lysine analogues may be subject to publication bias. Evidence of publication bias was not observed in trials reporting re-operation rates. Adjustment for these effects reduced the magnitude of estimated benefits but did not negate treatment effects. However, the apparent advantage of aprotinin over the lysine analogues was small and may be explained by publication bias and non-equivalent drug doses. Aprotinin did not increase the risk of myocardial infarction (RR 0.92, 95% CI 0.72 to 1.18), stroke (RR 0.76, 95% CI 0.35 to 1.64) renal dysfunction (RR 1.16, 95% CI 0.79 to 1.70) or overall mortality (RR 0.90, 95% CI 0.67 to 1.20). The analyses of myocardial infarction and death included data from the majority of subjects recruited into the clinical trials of aprotinin. However, under-reporting of renal events could explain the lack of effect seen with aprotinin. Similar trends were seen with the lysine analogues but data were sparse. These results conflict with the results of recently published non-randomised studies. AUTHORS' CONCLUSIONS: Anti-fibrinolytic drugs provide worthwhile reductions in blood loss and the need for allogeneic red cell transfusion. Based on the results of randomised trials their efficacy does not appear to be offset by serious adverse effects. In most circumstances the lysine analogues are probably as effective as aprotinin and are cheaper; the evidence is stronger for tranexamic acid than for aminocaproic acid. In high risk cardiac surgery, where there is a substantial probability of serious blood loss, aprotinin may be preferred over tranexamic acid. Aprotinin does not appear to be associated with an increased risk of vascular occlusion and death, but the data do not exclude an increased risk of renal failure. There is no need for further placebo-controlled trials of aprotinin or lysine analogues in cardiac surgery. The principal need is for large comparative trials to assess the relative efficacy, safety and cost-effectiveness of anti-fibrinolytic drugs in different surgical procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., & Yetisir, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400601 · Cited by 5,187
The Risk Associated with Aprotinin in Cardiac Surgery
Mangano, D. T., Tudor, I. C., & Dietzel, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051379 · Cited by 1,099
EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY
Royston, D., Taylor, K. M., Bidstrup, B. P., & Sapsford, R. N. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91190-1 · Cited by 677
Mannucci, P. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390407 · Cited by 557
Levi, M., Cromheecke, M. E., de Jonge, E., Prins, M. H., de Mol, B. J., Briët, E., & Büller, H. R. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01264-7 · Cited by 545
Bidstrup, B. P., Royston, D., Sapsford, R. N., Taylor, K. M., & Cosgrove, D. M. (1989) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)34573-8 · Cited by 526
The independent association of massive blood loss with mortality in cardiac surgery
Karkouti, K., Wijeysundera, D. N., Yau, T. M., Beattie, W. S., Abdelnaem, E., McCluskey, S. A., Ghannam, M., Yeo, E., Djaiani, G., & Karski, J. (2004) · Transfusion · doi:10.1111/j.1537-2995.2004.04144.x · Cited by 452
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
Vamvakas, E. C., & Blajchman, M. A. (2001) · Blood · doi:10.1182/blood.v97.5.1180 · Cited by 423
Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery
Mangano, D. T. (2007) · JAMA · doi:10.1001/jama.297.5.471 · Cited by 395
Laupacis, A., & Fergusson, D. (1997) · Anesthesia & Analgesia · doi:10.1097/00000539-199712000-00014 · Cited by 389
Self-citationAprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
Cosgrove, D. M., Heric, B., Lytle, B. W., Taylor, P. C., Novoa, R., Golding, L. A. R., Stewart, R. W., McCarthy, P. M., & Loop, F. D. (1992) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(92)90066-d · Cited by 375
Karkouti, K., Beattie, W. S., Dattilo, K. M., McCluskey, S. A., Ghannam, M., Hamdy, A., Wijeysundera, D. N., Fedorko, L., & Yau, T. M. (2006) · Transfusion · doi:10.1111/j.1537-2995.2006.00724.x · Cited by 338
Levy, J. H., Pifarré, R., Schaff, H. V., Horrow, J. C., Albus, R. A., Spiess, B. D., Rosengart, T. K., Murray, J., Clark, R. E., Smith, P., et al. (1995) · Circulation · doi:10.1161/01.cir.92.8.2236 · Cited by 307
The Dose-Response Relationship of Tranexamic Acid
Horrow, J. C., Van Riper, D. F., Strong, M. D., Grunewald, K. E., & Parmet, J. L. (1995) · Anesthesiology · doi:10.1097/00000542-199502000-00009 · Cited by 300
Sedrakyan, A., Treasure, T., & Elefteriades, J. A. (2004) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.03.041 · Cited by 279
Forgie, M. A. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.610 · Cited by 263
Prophylactic tranexamic acid decreases bleeding after cardiac operations
Horrow, J. C., Hlavacek, J., Strong, M. D., Collier, W., Brodsky, I., Goldman, S. M., & Goel, I. P. (1990) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)35634-x · Cited by 249
Carson, J. L., Terrin, M. L., Barton, F. B., Aaron, R., Greenburg, A. G., Heck, D. A., Magaziner, J., Merlino, F. E., Bunce, G., McClelland, B., et al. (1998) · Transfusion · doi:10.1046/j.1537-2995.1998.38698326331.x · Cited by 238
Self-citationHuët, C., Salmi, L. R., Fergusson, D., Koopman-van Gemert, A. W. M. M., Rubens, F., & Laupacis, A. (1999) · Anesthesia & Analgesia · doi:10.1213/00000539-199910000-00009 · Cited by 236
Self-citationMunoz, J. J., Birkmeyer, N. J. O., Birkmeyer, J. D., O’Connor, G. T., & Dacey, L. J. (1999) · Circulation · doi:10.1161/01.cir.99.1.81 · Cited by 185
Orpen, N. M., Little, C., Walker, G., & Crawfurd, E. J. P. (2006) · The Knee · doi:10.1016/j.knee.2005.11.001 · Cited by 164
Perioperative Parenteral Tranexamic Acid in Liver Tumor Resection
Wu, C.-C., Ho, W., Cheng, S., Yeh, D., Wen, M., Liu, T., & P??eng, F.-K. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000197561.70972.73 · Cited by 143
Prophylactic Treatment of Postperfusion Bleeding Using EACA
Rossi, A. J. D., Cernaianu, A. C., Botros, S. B., Lemole, G. M., & Moore, R. (1989) · CHEST Journal · doi:10.1378/chest.96.1.27 · Cited by 143
Brown, R. S., Thwaites, B. K., & Mongan, P. D. (1997) · Anesthesia & Analgesia · doi:10.1097/00000539-199711000-00003 · Cited by 122
Katsaros, D., Petricevic, M., SNOW, N. J., Woodhall, D. D., & Bergen, R. V. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(96)00022-7 · Cited by 112
Casati, V., Guzzon, D., Oppizzi, M., Bellotti, F., Franco, A., Gerli, C., Cossolini, M., Torri, G., Calori, G., Benussi, S., et al. (2000) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2000.108016 · Cited by 107
Salm, T. J. V., Kaur, S., Lancey, R., Okike, O. N., Pezzella, A. T., Stahl, R. F., Leone, L., Li, J., VALERI, C. R., & Michelson, A. D. (1996) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70112-5 · Cited by 106
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Moxey, A. J., Carless, P. A., O’Connell, D. L., McClelland, B., Henderson, K., Sly, K. A., Laupacis, A., & Fergusson, D. A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886 · Cited by 95
Self-citationDiprose, P., Herbertson, M., O'Shaughnessy, D. F., Deakin, C. D., & Gill, R. S. (2004) · British Journal of Anaesthesia · doi:10.1093/bja/aei044 · Cited by 94
Menichetti, A., Tritapepe, L., Ruvolo, G., Speziale, G., Cogliati, A. A., Giovanni, C. D., Pacilli, M. A., & Criniti, A. (1996) · PubMed · Cited by 92
Faught, C., Wells, P., Fergusson, D. A., & Laupacis, A. (1998) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(98)80061-8 · Cited by 91
Self-citationEconomic analysis of erythropoietin use in orthopaedic surgery
Coyle, D., Lee, Fergusson, D. A., & Laupacis (1999) · Transfusion Medicine · doi:10.1046/j.1365-3148.1999.009001021.x · Cited by 90
Self-citationPlatelet protection by low-dose aprotinin in cardiopulmonary bypass: Electron microscopic study
Lavee, J., Raviv, Z., Smolinsky, A., Savion, N., Varon, D., Goor, D. A., & Mohr, R. (1993) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(93)90484-y · Cited by 87
Aprotinin Versus Lysine Analogues: The Debate Continues
Royston, D. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00071-x · Cited by 81
Defraigne, J.-O., Pincemaïl, J., Larbuisson, R., et al. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01093-6 · Cited by 77
Carless, P. A., Moxey, A. J., Stokes, B., & Henry, D. A. (2005) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-5-19 · Cited by 62
Self-citationFerraris, V. A., Bridges, C. R., & Anderson, R. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066081 · Cited by 62
Vaněk, T., Jares, M., Fajt, R., Straka, Z., Jirásek, K., Kolesár, M., Brůček, P., & Malý, M. (2005) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2005.06.027 · Cited by 56
Andreasen, J. J., & Nielsen, C. (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.03.012 · Cited by 54
The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria
Whyte, G. S., & Savoia, H. (1997) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1997.tb123269.x · Cited by 53
Harmon, D. C., Ghori, K., Eustace, N. P., OʼCallaghan, S. J. F., O’Donnell, A., & Shorten, G. (2004) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03018488 · Cited by 48
Low-dose and high-dose aprotinin improve hemostasis in coronary operations
Speekenbrink, R. G. H., Wildevuur, C. R. H., Sturk, A., & Eijsman, L. (1996) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70281-7 · Cited by 48
Fergusson, D. A., vanWalraven, C., Coyle, D., Laupacis, A., & THEINTERNATIONALSTUDYOFPERIO (1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80005-4 · Cited by 46
Self-citationVamvakas, E. C. (2004) · Vox Sanguinis · doi:10.1111/j.0042-9007.2004.00394.x · Cited by 45
Tassani, P., Augustin, N., Barankay, A., Braun, S., Zaccaria, F., & Richter, J. A. (2000) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/jcan.2000.18328 · Cited by 42
Aprotinin in elective primary bypass surgeryGraft patency and clinical efficacy
Las, M., Welz, A., Kochs, M., Mayer, G. J., SCHWANDT, M., & Hannekum, A. (1995) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(05)80146-0 · Cited by 41
Klein, M. (1998) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(98)00192-4 · Cited by 40
The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery
Türköz, A., Çığlı, A., But, K., Sezgin, N., Türköz, R., Gülcan, Ö., & Ersoy, M. Ö. (2001) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/jcan.2001.26539 · Cited by 39
Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting
Bidstrup, B. P., Hunt, B. J., Sheikh, S., Parratt, R. N., Bidstrup, J. M., & Sapsford, R. N. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(99)01337-5 · Cited by 38
Postoperative use of aprotinin in cardiac operations: An alternative to its prophylactic use
Cicek, S. M., Demirkılıç, U., Özal, E., Kuralay, E., Bingöl, H., Tatar, H., & Öztürk, Ö. Y. (1996) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70004-1 · Cited by 29
International Aspects of the AIDS/HIV Epidemic
Kimball, A. M., Berkley, S., NGUGI, E. N., & Gayle, H. D. (1995) · Annual Review of Public Health · doi:10.1146/annurev.pu.16.050195.001345 · Cited by 23
Body, S. C., & Mazer, C. D. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000246810.88697.15 · Cited by 19
Beattie, W. S., & Karkouti, K. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000244541.78602.ee · Cited by 18
Stammers, A. H., Huffman, S. M., Alonso, A., Fristoe, L. W., Hill, G. E., Casebeer, D., Diego, R. P., & Song, Z. (1997) · Journal of ExtraCorporeal Technology · doi:10.1051/ject/1997293114 · Cited by 17
Aprotinin and Dipyridamole for the Safe Reduction of Postoperative Blood Loss
Cohen, G. N., Ivanov, J., Weisel, R. D., Rao, V., Mohabeer, M. K., & Mickle, D. A. G. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(97)01428-8 · Cited by 8
Cited by
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O’Connell, D. L., Stokes, B., Fergusson, D. A., & Ker, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub4 · Cited by 1,065
Self-citationRoberts, I., Shakur, H., Coats, T., Hunt, B., Balogun, E., Barnetson, L., Cook, L., Kawahara, T., Perel, P., Prieto-Merino, D., et al. (2013) · Health Technol Assess · doi:10.3310/hta17100 · Cited by 794
Bowen, T., Cicardi, M., Farkas, H., Bork, K., Longhurst, H. J., Zuraw, B., Aygoeren-Pürsün, E., Craig, T., Binkley, K., Hebert, J., et al. (2010) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-6-24 · Cited by 614
Metadata
- Authors
- Henry, D. A., Carless, P. A., Moxey, A. J., O'Connell, D., Stokes, B. J., McClelland, B., Laupacis, A., & Fergusson, D. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2007-10-17
- Issue
- 4
- Pages
- CD001886-CD001886
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4238817203
- Cited by
- 256
- References
- 58
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.